These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 16963587)

  • 1. Escitalopram for major depression in Parkinson's disease: an open-label, flexible-dosage study.
    Weintraub D; Taraborelli D; Morales KH; Duda JE; Katz IR; Stern MB
    J Neuropsychiatry Clin Neurosci; 2006; 18(3):377-83. PubMed ID: 16963587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Transient citalopram-induced auditory hallucinations in a patient with Parkinson's disease and depression.
    Wand AP
    Aust N Z J Psychiatry; 2012 Feb; 46(2):178. PubMed ID: 22311539
    [No Abstract]   [Full Text] [Related]  

  • 3. Escitalopram in the treatment of major depressive disorder in primary-care settings: an open-label trial.
    Chokka P; Legault M
    Depress Anxiety; 2008; 25(12):E173-81. PubMed ID: 19006260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effective dose of escitalopram in moderate versus severe DSM-IV major depression.
    Bech P; Andersen HF; Wade A
    Pharmacopsychiatry; 2006 Jul; 39(4):128-34. PubMed ID: 16871468
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Clinical efficacy and achievement of a complete remission in depression: increasing interest in treatment with escitalopram].
    Favré P
    Encephale; 2012 Feb; 38(1):86-96. PubMed ID: 22381728
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Citalopram and escitalopram in the treatment of major depressive disorder: a pooled analysis of 3 clinical trials.
    Li H; Li T; Li G; Luo J
    Ann Clin Psychiatry; 2014 Nov; 26(4):281-7. PubMed ID: 25401715
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An open-label multicentric study of the tolerability and response to escitalopram treatment in Indian patients with major depressive disorder.
    Pinto C; Trivedi JK; Vankar GK; Sharma PS; Narasimha V
    J Indian Med Assoc; 2007 Jul; 105(7):364, 366, 368 passim. PubMed ID: 18178988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Escitalopram.
    Aronson S; Delgado P
    Drugs Today (Barc); 2004 Feb; 40(2):121-31. PubMed ID: 15045034
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rapid improvement of depression and quality of life with escitalopram treatment in outpatients with breast cancer: a 12-week, open-label prospective trial.
    Park HY; Lee BJ; Kim JH; Bae JN; Hahm BJ
    Prog Neuropsychopharmacol Biol Psychiatry; 2012 Mar; 36(2):318-23. PubMed ID: 22142651
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mood and neuropsychological changes in women with midlife depression treated with escitalopram.
    Wroolie TE; Williams KE; Keller J; Zappert LN; Shelton SD; Kenna HA; Reynolds MF; Rasgon NL
    J Clin Psychopharmacol; 2006 Aug; 26(4):361-6. PubMed ID: 16855452
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized controlled trial of antidepressant continuation for major depression following traumatic brain injury.
    Rapoport MJ; Mitchell RA; McCullagh S; Herrmann N; Chan F; Kiss A; Feinstein A; Lanctôt KL
    J Clin Psychiatry; 2010 Sep; 71(9):1125-30. PubMed ID: 20441723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. An inflammatory biomarker as a differential predictor of outcome of depression treatment with escitalopram and nortriptyline.
    Uher R; Tansey KE; Dew T; Maier W; Mors O; Hauser J; Dernovsek MZ; Henigsberg N; Souery D; Farmer A; McGuffin P
    Am J Psychiatry; 2014 Dec; 171(12):1278-86. PubMed ID: 25017001
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and tolerability of reboxetine compared with citalopram: a double-blind study in patients with major depressive disorder.
    Langworth S; Bodlund O; Agren H
    J Clin Psychopharmacol; 2006 Apr; 26(2):121-7. PubMed ID: 16633139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Efficacy of escitalopram vs paroxetine on severe depression with associated anxiety: data from the "Boulenger" study].
    Chauvet-Gélinier JC
    Encephale; 2010 Oct; 36(5):425-32. PubMed ID: 21035633
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety and efficacy of oral escitalopram as continuation treatment of intravenous citalopram in patients with major depressive disorder.
    Schmitt L; Tonnoir B; Arbus C
    Neuropsychobiology; 2006; 54(4):201-7. PubMed ID: 17337913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and tolerability of escitalopram versus citalopram in major depressive disorder: a 6-week, multicenter, prospective, randomized, double-blind, active-controlled study in adult outpatients.
    Yevtushenko VY; Belous AI; Yevtushenko YG; Gusinin SE; Buzik OJ; Agibalova TV
    Clin Ther; 2007 Nov; 29(11):2319-32. PubMed ID: 18158074
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability, and cognition.
    Menza M; Marin H; Kaufman K; Mark M; Lauritano M
    J Neuropsychiatry Clin Neurosci; 2004; 16(3):315-9. PubMed ID: 15377738
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A randomized, double-blind, placebo-controlled study of citalopram in adolescents with major depressive disorder.
    von Knorring AL; Olsson GI; Thomsen PH; Lemming OM; Hultén A
    J Clin Psychopharmacol; 2006 Jun; 26(3):311-5. PubMed ID: 16702897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of comorbid anxiety and depression with escitalopram: results of a post-marketing surveillance study.
    Laux G; Friede M; Müller WE
    Pharmacopsychiatry; 2013 Jan; 46(1):16-22. PubMed ID: 22648305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.